You are here: Industry Insights > COVID-19 vaccine

News List

Pharma Sources Insight April 2022: An Overview on BIopharma and API in China and the World Pharma Sources Insight
March 29, 2022
Pharma Sources Insight APRIL 2022 focuses on the universal COVID-19 vaccine, Chinese API, pharma packaging, global biopharma trends and more.
Fighting Against COVID-19: Summary of Key Products PharmaSources/Recollect
February 22, 2022
Since the outbreak of COVID-19 in 2019, many kinds of COVID-19 vaccines, COVID-19 preventive drugs and COVID-19 therapeutic drugs have been approved worldwide.
Overview of COVID-19 Vaccination in Progress in China PharmaSources/Xiaoyaowan
August 06, 2021
Up to now, 10 COVID-19 vaccines have been marketed worldwide, including two RNA vaccines from Pfizer & BNT and Modernam, four adenoviral vector vaccines from AstraZeneca, Johnson & Johnson, Gamaleya and CanSino, three inactivated viral vaccines from CNBG
Opportunities for Africa in COVID-19 Vaccine Market Shem Oirere
January 14, 2021
Africa is pushing a bigger role in the global clinical trials and the manufacture of new COVID-19...
Designing the Messenger: Story of the mRNA Vaccine Neeta Ratanghayra
November 05, 2020
In early January this year, Chinese authorities shared the genetic sequence of SARS-CoV-2, the novel coronavirus.
Inactivated Virus Vaccines vs. mRNA Vaccines: Differences between China and the U.S. in Preferred Technologies for Developing COVID-19 Vaccines PharmaSources/Xiaoyaowan
November 13, 2020
The cumulative number of confirmed cases of COVID-19 has exceeded 11.30 million worldwide by July 5. The vaccine development has been in full swing in each country since the occurrence of the virus.
Pharmaceutical News of August | PharmaSources.com: COVID-19 PharmaSources/Caicai
September 23, 2020
AstraZeneca announced the initiation of Phase III clinical trial for its adenovirus vector-based COVID-19 vaccine: AZD1222 in the U.S. on Aug. 31, which has a code of D8110C00001 and is funded by the Biomedical Advanced Research and Development Authority
Pharmaceutical News of August | PharmaSources.com—Transaction & IPO PharmaSources/Caicai
September 23, 2020
Suzhou Vigonvita Life Sciences completed a new series of equity financing, with Qihoo 360, Share Venture, Ganzhou Qizhi Huikang, and Suzhou Meilingge becoming new shareholders of the company and the registered capital increasing to RMB5,769,231.
V-01 as a Sequential Booster Can Produce Good Protection against Omicron ---- Latest Phase III Data of COVID-19 Vaccine by Livzon Pharma PharmaSources.com
February 21, 2022
Global pandemic control is still facing enormous challenges after more than two years since the outbreak of the COVID-19.
Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine prnasia
February 15, 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Singapore Health Sciences Authority...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 116 117 Next page